Open Label, Proof of Concept, Phase I/II Study of the Safety, Tolerability and Efficacy of Intravenous Alpha-1 Antitrypsin (AAT) [Trade Name Glassia] in Type 1 Diabetes Mellitus

Trial Profile

Open Label, Proof of Concept, Phase I/II Study of the Safety, Tolerability and Efficacy of Intravenous Alpha-1 Antitrypsin (AAT) [Trade Name Glassia] in Type 1 Diabetes Mellitus

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Jul 2015

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Kamada
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jul 2015 According to Kamada media release, results have been published in Pediatric Diabetes, a peer-reviewed journal.
    • 06 Jul 2015 Results published in Kamada Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top